21 January 2022
Apollon Formularies Announces Appointment of Dr. the Honorable Archibald McDonald, Professor Emeritus, and Former University Dean, Faculty of Medical Sciences and Pro-Vice Chancellor, University of the West Indies as Director of Clinical Trials
· Professor McDonald is a recipient of the prestigious Order of
· Professor McDonald is a recipient of the Order of Distinction in the rank of Commander (CD)
· Professor McDonald is Current Chairman, Ministry of Health and Wellness Ethics Panel
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a
Professor McDonald was awarded the prestigious Order of
His academic awards include; the Vice Chancellor's Award for Excellence in the category, Outstanding Service to the University Community, MAJ Award for Distinguished Service to the Medical Profession, JEMA Award for Establishment and Continuing Contribution to the Evolution of Emergency Medicine in
Dr. McDonald is a Fellow of the Royal College of Surgeons of
He has published over 150 peer-reviewed scientific papers, abstracts, invited articles and book chapters, and has lectured extensively for many years at international and national meetings of medical and professional societies.
The appointment of Dr. McDonald is not a main Board appointment.
"Professor McDonald is a highly respected surgeon and experienced research physician; Apollon is honored to have him join our team as Director of Clinical Trials," stated Stephen D. Barnhill, MD. Executive Chairman and CEO of Apollon Formularies, plc. "We are excited to immediately begin working with Dr. McDonald to start human clinical trials to validate the success of our pre-clinical studies."
"I look forward to working with Dr. Barnhill, a pioneer in using artificial intelligence in medical cannabis formulation development, and the Apollon medical team on initiating human clinical trials in
On 19 July 2021, Apollon announced that its proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures by direct cytotoxicity.
June 28, 2021, Apollon announced that its proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing triple-negative breast cancer cells in 3D cell culture by direct cell cytotoxicity.
May 18, 2021, Apollon announced that its proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing HER2+ breast cancer cells in 3D cell culture by direct cytotoxicity.
The Directors of the Company accept responsibility for the contents of this announcement.
For additional information, please visit www.apollon.org.uk or contact:
Tel: +44 207 907 9314
Stene Jacobs firstname.lastname@example.org
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller email@example.com
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe firstname.lastname@example.org
Megan Ray email@example.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica, Ltd is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica and a contractual affiliate of Apollon. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to purchase cannabis under tripartite agreements from licensed cultivators, process, perform research and development, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision.